US equities |
NVDA $240.67 ▲+0.74% SPCX $173.84 ▲+1.60% MU $1,066.74 ▲+0.26% MRVL $285.00 ▲+5.07% AMD $656.88 ▲+3.98% SNDK $1,670.16 ▼-2.00% INTC $114.60 ▼-1.36% AVGO $378.26 ▲+4.34%
FinancialContent

Defiance Daily Target 2X Long LLY ETF (NY:LLYX)

24.60 +0.78 (+3.25%)
Delayed Quote Updated: 12:51 PM EDT, Oct 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Defiance Daily Target 2X Long LLY ETF

News headline image
LLY Stock Surges Pre-Market: Obesity, Diabetes Drugs Drive Strong FY26 Outlook ↗
Fourth-quarter revenue surged 43% to $19.3 billion, above Street estimates of $17.86 billion, according to Fiscal.ai data. 
Via Stocktwits
News headline image
ETFs Last Week: Thematic ETFs Gleamed Against Market Gloom ↗
Last week, thematic and leveraged ETFs performed well, such as DJTU, LLYX, NFXL, DECO, and MSTY, despite market concerns. Tech sector was hit by geopolitical tension and hawkish central bank comments.... 
Via Benzinga
Topics ETFs Economy
News headline image
Want To Bet On Ozempic, Wegovy Success? Defiance Introduces Leveraged ETF To Capture Novo Nordisk Momentum ↗
Defiance ETFs introduces NVOX, a leveraged ETF offering 2X exposure to Novo Nordisk's stock price movements, targeting the booming weight loss market with tactical trading opportunities. 
Via Benzinga
Topics ETFs
News headline image
Defiance ETFs Surpass $8 Billion in Assets Under Management
From Defiance ETFs
Via GlobeNewswire
FDA Clears Popular Weight-Loss Drugs Of Suicide Risk After Review Of Over 100K Patients, Asks Drugmakers To Remove Warnings ↗
Via Stocktwits